CTNM
insider transactionsContineum Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 90d
-12.5K
0 buy · 12.5K sell
Net value · 90d
-$165.6K
$0 in · $165.6K out
Sentiment · 90d
Net selling
0% buying · 100% selling
Open-market trades · 90d
4
0 buy · 12.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Scientific Officer · 10b5-1
$54.9K
4.2K sh · $13.16
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$4.2K
300 sh · $13.84
Own -0%
-
Sell·S
Chief Scientific Officer · 10b5-1
$50.5K
3.9K sh · $13.06
Own -3%
-
Sell·S
Chief Scientific Officer · 10b5-1
$56.0K
4.2K sh · $13.43
Own -3%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 1, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 4.2K | $54.9K |
| May 1, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 300 | $4.2K |
| May 1, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 3.9K | $50.5K |
| Apr 6, 2026 | Daniel S. Lorrain 10b5-1 | Sell S | 4.2K | $56.0K |
About CTNM insider trading
This page tracks insider transactions for Contineum Therapeutics, Inc. (CTNM) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.